Table 1.

Overall mortality and mortality rate ratios at diagnosis/index date for soft tissue sarcoma patients (N = 1246) and the general comparison cohort (N = 6230)

		STS patient mortality % (95% CI)	General comparison mortality % (95% CI)	Crude MRR (95% CI)	Adjusted MRR (95% CI)*
0 to 5 years
Gender	Female	40.2 (36.4-44.3)	10.7 (9.7-11.9)	4.8 (4.1-5.7)	4.7 (3.9-5.6)
	Male	41.6 (37.9-45.5)	13.5 (12.4-14.7)	3.9 (3.4-4.6)	4.2 (3.6-4.9)
Age (years)	0-39	27.2 (22.5-32.7)	0.3 (0.1-0.7)	116.7 (42.7-318.6)	110.8 (40.5-303.0)
	40-59	24.4 (20.3-29.2)	2.4 (1.8-3.3)	11.5 (8.0-16.4)	11.0 (7.6-15.8)
	60-79	53.9 (49.5-58.5)	16.5 (15.1-18.1)	4.7 (4.0-5.5)	4.4 (3.7-5.1)
	≥ 80	72.2 (64.3-79.6)	51.2 (47.4-55.1)	1.9 (1.5-2.4)	1.9 (1.5-2.4)
Comorbidity	None	34.9 (31.9-38.0)	7.0 (6.3-7.8)	6.2 (5.4-7.2)	6.6 (5.7-7.7)
	Low	52.3 (43.3-62.0)	24.3 (21.2-27.8)	2.9 (2.1-3.9)	3.0 (2.2-4.1)
	Moderate	60.6 (51.5-69.7)	34.2 (29.7-39.2)	2.5 (1.9-3.4)	2.8 (2.1-3.8)
	High	68.7 (58.8-78.2)	48.9 (43.0-55.3)	1.8 (1.3-2.4)	2.0 (1.4-2.7)
Total		41.0 (38.3-43.7)	12.2 (11.4-13.0)	4.3 (3.8-4.8)	4.4 (3.9-4.9)
5 to 10 years
Gender	Female	16.0 (12.3-20.6)	11.7 (10.4-13.1)	1.4 (1.1-2.0)	1.8 (1.3-2.5)
	Male	19.2 (15.4-23.9)	15.2 (13.8-16.7)	1.3 (1.0-1.7)	1.5 (1.2-2.0)
Age (years)	0-39	8.1 (5.1-13.0)	0.8 (0.4-1.4)	11.1 (5.1-24.6)	11.1 (5.0-24.6)
	40-59	12.4 (8.8-17.3)	4.4 (3.5-5.6)	3.1 (2.0-4.8)	2.9 (1.8-4.4)
	60-79	28.4 (22.3-35.8)	24.3 (22.2-26.5)	1.2 (0.9-1.6)	1.2 (0.9-1.6)
	≥ 80	60.0 (42.8-77.7)	64.0 (57.9-70.0)	1.0 (0.6-1.7)	1.1 (0.7-1.7)
Comorbidity	None	13.7 (11.1-16.9)	11.1 (10.1-12.2)	1.4 (1.1-1.8)	1.5 (1.2-2.0)
	Low	41.3 (26.5-60.4)	23.0 (18.8-27.9)	1.3 (0.8-2.3)	1.6 (0.9-2.8)
	Moderate	44.9 (30.6-62.3)	23.9 (19.9-28.6)	1.9 (1.1-3.3)	2.8 (1.6-4.9)
	High	32.9 (17.8-55.7)	20.1 (15.6-25.6)	0.7 (0.3-1.5)	0.9 (0.4-2.0)
Total		17.7 (14.9-20.9)	13.5 (12.5-14.5)	1.4 (1.1-1.7)	1.6 (1.3-2.0)

NOTES: Abbreviations: STS soft tissue sarcoma, MRR mortality rate ratio, CI confidence interval. *Adjusted for age, gender, and level of comorbidity.